pharma

By Jonah Comstock July 6, 2018
Pharma companies are getting more and more open about their digital health initiatives, which has given MobiHealthNews more opportunities this quarter than usual to chronicle pharma’s efforts around adherence, clinical trials, and the burgeoning world of digital therapeutics. In addition, at the BIO conference in Boston this quarter MobiHealthNews heard pharma innovation leaders share their...
By Jonah Comstock June 22, 2018
Medication management and adherence app maker Medisafe has announced a partnership with Boehringer Ingelheim following a successful pilot.  Medisafe will offer a wraparound app experience that incorporates Pradaxa-specific educational information into a special version of its app, which patients will be directed to when they're prescribed the drug. "Pradaxa is not different than any other...
By Jonah Comstock June 14, 2018
Benchling, which offers a software suite for improving collaboration and productivity among life sciences and biotech researchers, has raised $14.5 million in series B funding. Benchmark led the round, with additional participation by F-Prime Capital and returning investor Thrive Capital. “Just as computer science has changed the world and transformed every industry, we think that in 10 to 20...
By Jonah Comstock May 16, 2018
Cambridge, Massachusetts-based sensor maker MC10, known for its flexible and stretchable electronics, has received its first FDA 510(k) clearance for the BioStamp nPoint system. BioStamp nPoint is a more advanced version of the company's non-FDA cleared BioStampRC. "BiostampRC was primarily developed as an investigational tool, primarily used by academia, as well as by pharmaceutical companies,...
By MobiHealthNews April 13, 2018
Pharma companies have been eying digital health with interest, and the first quarter of 2018 was no exception. With the exception of some medication adherence-focused technologies — such as an edible QR code intended to assist with medication dosing — news tended to center around digitally-enabled clinical trials, rollouts or pilots of pharma-focused digital tools, and major deals or...
By Jonah Comstock December 27, 2017
Digital health in pharma definitely had a milestone moment in the fourth quarter with the FDA approval of Abilify MyCite, a new, sensor-enabled version of Otsuka’s drug for schizophrenia powered by Proteus Digital Health’s ingestible sensor technology. In addition to that, the quarter saw numerous other moves by pharma companies around clinical trials, chronic disease management, mental health,...
By Dave Muoio December 1, 2017
Editor's note: Since publication, some of this story's quotes have been edited for clarity. With billions of dollars and countless hours of human effort spent each year validating new drugs, devices, and medical interventions, it’s little surprise that the healthcare industry is turning to technology to streamline the process. From participant recruitment to data collection to adherence, clinical...
By Jonah Comstock October 20, 2017
Pharma companies were fairly active in digital health in the third quarter of 2017, especially in the areas of diabetes and respiratory disease. Read on for a round-up of notable events. Diabetes management Abbott Diabetes Care had a big quarter for its Freestyle Libre system, both in the United States and abroad. First, in July, Abbott and Bigfoot Biomedical entered into an agreement to develop...
By Jeff Lagasse September 6, 2017
Truveris, a healthcare technology company focused cloud-based data analytics solutions for the $450 billion prescription benefits industry, today announced that the company has secured $25 million in a new round of funding to accelerate its growth strategies.   The Series D round was led by McKesson Ventures, and included Canaan Partners, New Leaf Venture Partners, Tribeca Venture Partners, and...
By Jeff Lagasse August 23, 2017
Precision medicine company GNS Healthcare has raised an additional $6 million in equity from Amgen Ventures, with participation from existing investor Alexandria Real Estate Equities. The funds will be used to further develop the company's REFS causal machine learning and simulation platform -- as well as solutions across drug discovery and development, value-based drug solutions, and care...